Fresenius, via its operating company Fresenius Kabi, announced the immediate availability in the United States of its biosimilar Tyenne (tocilizumab-aazg), in a subcutaneous formulation, which will increase access to affordable and cost-effective treatment options for use in the treatment of chronic autoimmune diseases.
Tyenne is indicated for use in the treatment of chronic autoimmune diseases for certain indications of the reference product, Actemra (tocilizumab, Biogen). Fresenius Kabi
JULY 10, 2024